SM2275 / StarMab Biomed - LARVOL DELTA

Phase I Study of SM2275 Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Beijing StarMab Biomed Technology Ltd

First-in-human • New P1 trial • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • EGFR • PD-L1

SM2275, A tetraspecific, dual EGFR and PD-L1-targeting, conditionally activating co-stimulatory CD28 and simultaneously blocking PD-1/PD-L1 signaling to promoting fully activated T cell killing effects on tumor cells (AACR 2024) - "SM2275 is a novel dual-EGFR & PD-L1-targeting, conditional CD28 agonistic antibody. It demonstrated promising efficacy and favorable safety profile in preclinical studies via a unique mechanism of action."

Tumor cell • Oncology • Solid Tumor • EGFR • IFNG • IL2

StarMab BioMed’s First-in-Class, Dual-Target Anti-Tumor Drug SM2275 for Novel Immunotherapy Receives FDA IND Approval (FOX40) - "Beijing StarMab BioMed Technology , Ltd...announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for SM2275...Preclinical studies have confirmed SM2275’s potent and sustained antitumor activity across multiple solid tumor models."

IND • Solid Tumor